Array BioPharma's colorectal cancer combo treatment meets main goals [Reuters (UK)]
Array Technologies, Inc. (ARRY)
Last array technologies, inc. earnings: 5/7 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.arraybiopharma.com/investor-overview
Company Research
Source: Reuters
Array BioPharma's colorectal cancer combo treatment meets main goals - Reuters 3 Min Read (Reuters) - Array BioPharma Inc’s cocktail of three therapies helped patients with a type of colorectal cancer live longer than those on standard treatment, according to interim results of a late-stage study on Tuesday. The combination therapy, comprising Array’s Braftovi and Mektovi and Eli Lilly and Co’s Erbitux, helped half the patients enrolled in the study survive nine months. This was in comparison to the standard regimen of Erbitux and chemotherapy irinotecan, which showed a median overall survival of 5.4 months in patients. Array’s combination also helped reduce the risk of death from colorectal cancer by 48% compared to the standard of care in patients, with a gene mutation known as BRAF V600E, whose cancer had progressed after one or two other therapies. The mutation occurs in up to 15% of metastatic colorectal cancer patients, and there are no FDA-approved treatments for the condition,
Show less
Read more
Impact Snapshot
Event Time:
ARRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARRY alerts
High impacting Array Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
ARRY
News
- Array Technologies, Inc. (ARRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release [Yahoo! Finance]Yahoo! Finance
- Array Technologies (NASDAQ:ARRY) Is Experiencing Growth In Returns On Capital [Yahoo! Finance]Yahoo! Finance
- ARRY vs. ENPH: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]Yahoo! Finance
- Array Hosts U.S. Energy Secretary Granholm, New Mexico Senators to Break Ground on New Solar Manufacturing Facility [Yahoo! Finance]Yahoo! Finance
- Array Hosts U.S. Energy Secretary Granholm, New Mexico Senators to Break Ground on New Solar Manufacturing FacilityGlobeNewswire
ARRY
Earnings
- 2/27/24 - Beat
ARRY
Sec Filings
- 4/22/24 - Form 4
- 4/10/24 - Form ARS
- 4/10/24 - Form DEFA14A
- ARRY's page on the SEC website